The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Biomarkers / blood Biopsy Genetic Testing Humans Kidney Diseases / blood Paraproteinemias / blood

Journal

Nature reviews. Nephrology
ISSN: 1759-507X
Titre abrégé: Nat Rev Nephrol
Pays: England
ID NLM: 101500081

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 5 12 2018
medline: 4 12 2019
entrez: 5 12 2018
Statut: ppublish

Résumé

The term monoclonal gammopathy of renal significance (MGRS) was introduced by the International Kidney and Monoclonal Gammopathy Research Group (IKMG) in 2012. The IKMG met in April 2017 to refine the definition of MGRS and to update the diagnostic criteria for MGRS-related diseases. Accordingly, in this Expert Consensus Document, the IKMG redefines MGRS as a clonal proliferative disorder that produces a nephrotoxic monoclonal immunoglobulin and does not meet previously defined haematological criteria for treatment of a specific malignancy. The diagnosis of MGRS-related disease is established by kidney biopsy and immunofluorescence studies to identify the monotypic immunoglobulin deposits (although these deposits are minimal in patients with either C3 glomerulopathy or thrombotic microangiopathy). Accordingly, the IKMG recommends a kidney biopsy in patients suspected of having MGRS to maximize the chance of correct diagnosis. Serum and urine protein electrophoresis and immunofixation, as well as analyses of serum free light chains, should also be performed to identify the monoclonal immunoglobulin, which helps to establish the diagnosis of MGRS and might also be useful for assessing responses to treatment. Finally, bone marrow aspiration and biopsy should be conducted to identify the lymphoproliferative clone. Flow cytometry can be helpful in identifying small clones. Additional genetic tests and fluorescent in situ hybridization studies are helpful for clonal identification and for generating treatment recommendations. Treatment of MGRS was not addressed at the 2017 IKMG meeting; consequently, this Expert Consensus Document does not include any recommendations for the treatment of patients with MGRS.

Identifiants

DOI: 10.1038/s41581-018-0077-4 PMID: 30510265 PMC: PMC7136169
pubmed: 30510265
doi: 10.1038/s41581-018-0077-4
pii: 10.1038/s41581-018-0077-4
pmc: PMC7136169
doi:

Substances chimiques

Biomarkers 0

Types de publication

Consensus Development Conference Journal Article Practice Guideline Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

45-59

Subventions

Organisme : BLRD VA
ID : I01 BX001192
Pays : United States
Organisme : CSRD VA
ID : I01 CX001326
Pays : United States
Organisme : BLRD VA
ID : IP1 BX001595
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK079337
Pays : United States

Commentaires et corrections

Type : ErratumIn

Références

Kyle, R. A. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am. J. Med. 64, 814–826 (1978).
pubmed: 645746
Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538–e548 (2014).
pubmed: 25439696 doi: 10.1016/S1470-2045(14)70442-5
Dimopoulos, M. A. et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s macroglobulinemia. J. Clin. Oncol. 27, 120–126 (2009).
pubmed: 19047284 doi: 10.1200/JCO.2008.17.7865
Strati, P. & Shanafelt, T. D. Monoclonal B cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood 126, 454–462 (2015).
pubmed: 26065657 pmcid: 4624440 doi: 10.1182/blood-2015-02-585059
Bence Jones, H. On a new substance occurring in the urine of a patient with mollities ossium. Philos. Trans. R. Soc. B. Biol. Sci. 138, 55–62 (1848).
doi: 10.1098/rstl.1848.0003
Steensma, D. P. & Kyle, R. A. A history of the kidney in plasma cell disorders. Contrib. Nephrol. 153, 5–24 (2007).
pubmed: 17075221 doi: 10.1159/000096757
Von Rustizky, J. Multiples myelom. Deutsch. Z. Chir. 3, 162–172 (1873).
doi: 10.1007/BF02911073
Decastello, A. Beitrage zur Kenntnis der Benc-Jonesschen Albuminurie [German]. Z. Kin. Med. 67, 319–343 (1909).
Koss, M. N., Pirani, C. L. & Osserman, E. F. Experimental Bence Jones cast nephropathy. Lab. Invest. 34, 579–591 (1976).
pubmed: 778484
Paueksakon, P., Revelo, M. P., Horn, R. G., Shappell, S. & Fogo, A. B. Monoclonal gammopathy: significance and possible causality in renal disease. Am. J. Kidney Dis. 42, 87–95 (2003).
pubmed: 12830460 doi: 10.1016/S0272-6386(03)00412-8
Higgins, L. et al. Kidney involvement of patients with Waldenström macroglobulinemia and other IgM-producing B cell lymphoproliferative disorders. Clin. J. Am. Soc. Nephrol. 13, 1037–1046 (2018).
pubmed: 18632851 pmcid: 2518806 doi: 10.2215/CJN.01600408
Chauvet, S. et al. Kidney diseases associated with monoclonal immunoglobulin M-secreting B cell lymphoproliferative disorders: a case series of 35 patients. Am. J. Kidney Dis. 66, 756–767 (2015).
pubmed: 25987261 doi: 10.1053/j.ajkd.2015.03.035
Vos, J. M. et al. Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. Br. J. Haematol. 175, 623–630 (2016).
pubmed: 27468978 doi: 10.1111/bjh.14279
Strati, P. et al. Renal complications in chronic lymphocytic leukemia and monoclonal B cell lymphocytosis: the Mayo Clinic experience. Haematologica 100, 1180–1188 (2015).
pubmed: 26088927 pmcid: 4800708 doi: 10.3324/haematol.2015.128793
Pozzi, C. et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am. J. Kidney Dis. 42, 1154–1163 (2003).
pubmed: 14655186 doi: 10.1053/j.ajkd.2003.08.040
Kyle, R. A. & Bayrd, E. D. Amyloidosis: review of 236 cases. Medicine (Baltimore) 54, 271–299 (1975).
doi: 10.1097/00005792-197507000-00001
Solomon, A., Weiss, D. T. & Kattine, A. A. Nephrotoxic potential of Bence Jones proteins. N. Engl. J. Med. 324, 1845–1851 (1991).
pubmed: 1904132 doi: 10.1056/NEJM199106273242603
Sirac, C. et al. Animal models of monoclonal immunoglobulin-related renal diseases. Nat. Rev. Nephrol. 14, 246–264 (2018).
pubmed: 29456245 doi: 10.1038/nrneph.2018.8
Merlini, G. & Stone, M. J. Dangerous small B cell clones. Blood 108, 2520–2530 (2006).
pubmed: 16794250 doi: 10.1182/blood-2006-03-001164
Glavey, S. V. & Leung, N. Monoclonal gammopathy: the good, the bad and the ugly. Blood Rev. 30, 223–231 (2016).
pubmed: 26732417 doi: 10.1016/j.blre.2015.12.001
Gertz, M. A. et al. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol. Dial. Transplant. 24, 3132–3137 (2009).
pubmed: 19403931 doi: 10.1093/ndt/gfp201
Zand, L. et al. Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. Leuk. Lymphoma 56, 3357–3364 (2015).
pubmed: 25860232 doi: 10.3109/10428194.2015.1040011
Bridoux, F. et al. Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features. Kidney Int. 62, 1764–1775 (2002).
pubmed: 12371978 doi: 10.1046/j.1523-1755.2002.00628.x
Nasr, S. H. et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J. Am. Soc. Nephrol. 20, 2055–2064 (2009).
pubmed: 19470674 pmcid: 2736767 doi: 10.1681/ASN.2009010110
Chauvet, S. et al. Treatment of B cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Blood 129, 1437–1447 (2017).
pubmed: 28069603 doi: 10.1182/blood-2016-08-737163
Czarnecki, P. G. et al. Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits. Kidney Int. 75, 420–427 (2009).
pubmed: 19037251 doi: 10.1038/ki.2008.577
Leung, N. et al. Long-term outcome of renal transplantation in light-chain deposition disease. Am. J. Kidney Dis. 43, 147–153 (2004).
pubmed: 14712438 doi: 10.1053/j.ajkd.2003.09.020
Said, S, M. et al. Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft. Kidney Int. 94, 159–169 (2011).
pubmed: 20876681 pmcid: 3022233 doi: 10.2215/CJN.05750710
Cohen, C. et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int. 88, 1135–1143 (2015).
pubmed: 26176826 doi: 10.1038/ki.2015.201
Hassoun, H. et al. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant. 42, 405–412 (2008).
pubmed: 18574442 doi: 10.1038/bmt.2008.179
Sayed, R. H. et al. Natural history and outcome of light chain deposition disease. Blood 126, 2805–2810 (2015).
pubmed: 26392598 pmcid: 4732758 doi: 10.1182/blood-2015-07-658872
Vignon, M. et al. Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients. Leukemia 31, 123–129 (2017).
pubmed: 27435002 doi: 10.1038/leu.2016.195
Leung, N. et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 120, 4292–4295 (2012).
pubmed: 23047823 doi: 10.1182/blood-2012-07-445304
Fermand, J. P. et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood 122, 3583–3590 (2013).
pubmed: 24108460 doi: 10.1182/blood-2013-05-495929
Bridoux, F. et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 87, 698–711 (2015).
pubmed: 25607108 doi: 10.1038/ki.2014.408
Kyle, R. A. et al. Progression in smoldering Waldenström macroglobulinemia: long-term results. Blood 119, 4462–4466 (2012).
pubmed: 22451426 pmcid: 3362362 doi: 10.1182/blood-2011-10-384768
Kyle, R. A. & Greipp, P. R. Smoldering multiple-myeloma. N. Engl. J. Med. 302, 1347–1349 (1980).
pubmed: 7374679 doi: 10.1056/NEJM198006123022405
Li, S. J. et al. Renal involvement in non-Hodgkin lymphoma: proven by renal biopsy. PLOS ONE 9, e95190 (2014).
pubmed: 24733356 pmcid: 3986362 doi: 10.1371/journal.pone.0095190
Poitou-Verkinder, A. L. et al. The spectrum of kidney pathology in B cell chronic lymphocytic leukemia/ small lymphocytic lymphoma: a 25-year multicenter experience. PLOS ONE 10, e0119156 (2015).
pubmed: 25811382 pmcid: 4374947 doi: 10.1371/journal.pone.0119156
Da’as, N. et al. Kidney involvement and renal manifestations in non-Hodgkin’s lymphoma and lymphocytic leukemia: a retrospective study in 700 patients. Eur. J. Haematol. 67, 158–164 (2001).
pubmed: 11737248 doi: 10.1034/j.1600-0609.2001.5790493.x
Luciano, R. L. & Brewster, U. C. Kidney involvement in leukemia and lymphoma. Adv. Chronic Kidney Dis. 21, 27–35 (2014).
doi: 10.1053/j.ackd.2013.07.004
Ravindran, A., Go, R. S., Fervenza, F. C. & Sethi, S. Thrombotic microangiopathy associated with monoclonal gammopathy. Kidney Int. 91, 691–698 (2017).
pubmed: 27998645 doi: 10.1016/j.kint.2016.09.045
Said, S. M. et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin. J. Am. Soc. Nephrol. 8, 1515–1523 (2013).
pubmed: 23704299 pmcid: 3805078 doi: 10.2215/CJN.10491012
Nasr, S. H. et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin. J. Am. Soc. Nephrol. 6, 775–784 (2011).
pubmed: 29052601 doi: 10.1038/modpathol.2017.124
Gibier, J. B. et al. Intratubular amyloid in light chain cast nephropathy is a risk factor for systemic light chain amyloidosis. Mod. Pathol. 31, 452–462 (2017).
pubmed: 21441134 pmcid: 3069369 doi: 10.2215/CJN.08300910
Grove, P., Neale, P. H., Peck, M., Schiller, B. & Haas, M. Monoclonal immunoglobulin G
pubmed: 9556416
Rosenstock, J. L. et al. Fibrillary and immunotactoid glomerulonephritis: distinct entities with different clinical and pathologic features. Kidney Int. 63, 1450–1461 (2003).
pubmed: 12631361 doi: 10.1046/j.1523-1755.2003.00853.x
Nasr, S. H. et al. DNAJB9 is a specific immunohistochemical marker for fibrillary glomerulonephritis. Kidney Int. Rep. 3, 56–64 (2018).
pubmed: 29340314 doi: 10.1016/j.ekir.2017.07.017
Dasari, S. et al. DnaJ heat shock protein family B member 9 is a novel biomarker for fibrillary GN. J. Am. Soc. Nephrol. 29, 51–56 (2018).
pubmed: 29097623 doi: 10.1681/ASN.2017030306
Alexander, M. P. et al. Congophilic fibrillary glomerulonephritis: a case series. Am. J. Kidney Dis. 72, 325–336 (2018).
Nasr, S. H. et al. Immunotactoid glomerulopathy: clinicopathologic and proteomic study. Nephrol. Dial. Transplant. 27, 4137–4146 (2012).
pubmed: 22872726 doi: 10.1093/ndt/gfs348
Karras, A. et al. Renal involvement in monoclonal (type I) cryoglobulinemia: two cases associated with IgG
pubmed: 12407656 doi: 10.1053/ajkd.2002.36350
Ojemakinde, K., Turbat-Herrera, E. A., Zeng, X., Gu, X. & Herrera, G. A. The many faces of cryoglobulinemic nephropathy: a clinico-pathologic study of 47 cases with emphasis on the value of electron microscopy. Ultrastruct. Pathol. 38, 367–376 (2014).
pubmed: 25191813 doi: 10.3109/01913123.2014.952803
Heher, E. C., Rennke, H. G., Laubach, J. P. & Richardson, P. G. Kidney disease and multiple myeloma. Clin. J. Am. Soc. Nephrol. 8, 2007–2017 (2013).
pubmed: 23868898 pmcid: 3817918 doi: 10.2215/CJN.12231212
Nasr, S. H. et al. Dysproteinemia, proteinuria, and glomerulonephritis. Kidney Int. 69, 772–775 (2006).
pubmed: 16395248 doi: 10.1038/sj.ki.5000123
Stokes, M. B. et al. Light chain proximal tubulopathy: clinical and pathologic characteristics in the modern treatment era. J. Am. Soc. Nephrol. 27, 1555–1565 (2015).
pubmed: 26374607 pmcid: 4849818 doi: 10.1681/ASN.2015020185
Kapur, U., Barton, K., Fresco, R., Leehey, D. J. & Picken, M. M. Expanding the pathologic spectrum of immunoglobulin light chain proximal tubulopathy. Arch. Pathol. Lab. Med. 131, 1368–1372 (2007).
pubmed: 17824791 doi: 10.5858/2007-131-1368-ETPSOI
Larsen, C. P. et al. The morphologic spectrum and clinical significance of light chain proximal tubulopathy with and without crystal formation. Mod. Pathol. 24, 1462–1469 (2011).
pubmed: 21701535 doi: 10.1038/modpathol.2011.104
Herrera, G. A. Proximal tubulopathies associated with monoclonal light chains: the spectrum of clinicopathologic manifestations and molecular pathogenesis. Arch. Pathol. Lab. Med. 138, 1365–1380 (2014).
pubmed: 25268200 doi: 10.5858/arpa.2013-0493-OA
El Hamel, C. et al. Crystal-storing histiocytosis with renal Fanconi syndrome: pathological and molecular characteristics compared with classical myeloma-associated Fanconi syndrome. Nephrol. Dial. Transplant. 25, 2982–2990 (2010).
pubmed: 20356978 doi: 10.1093/ndt/gfq129
Koo, H., Oh, D. H., Chun, Y. S. & Kim, J. C. A case of crystalline keratopathy in monoclonal gammopathy of undetermined significance (MGUS). Korean J. Ophthalmol. 25, 202–205 (2011).
doi: 10.3341/kjo.2011.25.3.202
Dogan, S., Barnes, L. & Cruz-Vetrano, W. P. Crystal-storing histiocytosis: report of a case, review of the literature (80 cases) and a proposed classification. Head Neck Pathol. 6, 111–120 (2012).
pubmed: 22430767 pmcid: 3311947 doi: 10.1007/s12105-011-0326-3
Kanagal-Shamanna, R. et al. Crystal-storing histiocytosis: a clinicopathological study of 13 cases. Histopathology 68, 482–491 (2016).
pubmed: 26118455 doi: 10.1111/his.12768
de Alba Campomanes, A. G. et al. Crystal-storing histiocytosis and crystalline keratopathy caused by monoclonal gammopathy of undetermined significance. Cornea 28, 1081–1084 (2009).
pubmed: 19724196 doi: 10.1097/ICO.0b013e318199f73b
Gupta, V., El Ters, M., Kashani, K., Leung, N. & Nasr, S. H. Crystalglobulin-induced nephropathy. J. Am. Soc. Nephrol. 26, 525–529 (2015).
pubmed: 25190731 doi: 10.1681/ASN.2014050509
Leung, N., Buadi, F., Song, K. W., Magil, A. B. & Cornell, L. D. A case of bilateral renal arterial thrombosis associated with cryocrystalglobulinaemia. Nephrol. Dial. Transplant. 3, 74–77 (2010).
Ball, N. J., Wickert, W., Marx, L. H. & Thaell, J. F. Crystalglobulinemia syndrome. A manifestation of multiple myeloma. Cancer 71, 1231–1234 (1993).
pubmed: 8435798 doi: 10.1002/1097-0142(19930215)71:4<1231::AID-CNCR2820710410>3.0.CO;2-J
Nasr, S. H. et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin. J. Am. Soc. Nephrol. 7, 231–239 (2012).
pubmed: 22156754 doi: 10.2215/CJN.08640811
Lin, J. et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J. Am. Soc. Nephrol. 12, 1482–1492 (2001).
pubmed: 11423577 doi: 10.1681/ASN.V1271482
Bridoux, F. et al. Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management. Kidney Int. 91, 423–434 (2017).
pubmed: 27773425 doi: 10.1016/j.kint.2016.09.004
Nasr, S. H. et al. Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int. 65, 85–96 (2004).
pubmed: 14675039 doi: 10.1111/j.1523-1755.2004.00365.x
Bhutani, G. et al. Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. Mayo Clin. Proc. 90, 587–596 (2015).
pubmed: 25939936 doi: 10.1016/j.mayocp.2015.01.024
Vignon, M. et al. The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits. Kidney Int. 91, 720–728 (2017).
pubmed: 28069266 doi: 10.1016/j.kint.2016.10.026
Lloyd, I. E. et al. C3 glomerulopathy in adults: a distinct patient subset showing frequent association with monoclonal gammopathy and poor renal outcome. Clin. Kidney J. 9, 794–799 (2016).
pubmed: 27994856 pmcid: 5162413 doi: 10.1093/ckj/sfw090
Zand, L. et al. C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am. J. Kidney Dis. 62, 506–514 (2013).
pubmed: 23623956 pmcid: 4435575 doi: 10.1053/j.ajkd.2013.02.370
Sethi, S. et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am. J. Kidney Dis. 56, 977–982 (2010).
pubmed: 20832153 pmcid: 3970198 doi: 10.1053/j.ajkd.2010.06.021
Kyle, R. A. et al. Prevalence of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 354, 1362–1369 (2006).
pubmed: 16571879 doi: 10.1056/NEJMoa054494
Larsen, C. P. et al. Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits. Kidney Int. 88, 867–873 (2015).
pubmed: 26154922 pmcid: 4687465 doi: 10.1038/ki.2015.195
Lloyd, I. E. & Khalighi, M. A. Glomerulonephritis with masked monotypic immunoglobulin deposits and concurrent lymphomatous infiltration. Am. J. Kidney Dis. 68, 640–644 (2016).
pubmed: 27337992 doi: 10.1053/j.ajkd.2016.05.012
Yandrapalli, S., Gupta, S., Papanagnou, A., Karass, M. & Chugh, S. Thrombotic microangiopathy in renal transplanted patients: analysis of nationwide inpatient sample. Am. J. Kidney Dis. 69, A103 (2017).
Mahmood, U. et al. Monoclonal gammopathy of renal significance triggering atypical haemolytic uraemic syndrome. Nephrology 22, 15–17 (2017).
pubmed: 28176474 doi: 10.1111/nep.12934
Blanc, C. et al. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. J. Immunol. 194, 5129–5138 (2015).
pubmed: 25917093 doi: 10.4049/jimmunol.1402770
Modesto-Segonds, A., Rey, J. P., Orfila, C., Huchard, G. & Suc, J. M. Renal involvement in POEMS syndrome. Clin. Nephrol. 43, 342–345 (1995).
pubmed: 7634552
Nakamoto, Y., Imai, H., Yasuda, T., Wakui, H. & Miura, A. B. A spectrum of clinicopathological features of nephropathy associated with POEMS syndrome. Nephrol. Dial. Transplant. 14, 2370–2378 (1999).
pubmed: 10528660 doi: 10.1093/ndt/14.10.2370
Ye, W. et al. Renal impairment in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes syndrome: incidence, treatment and outcome. Nephrol. Dial. Transplant. 31, 275–283 (2016).
pubmed: 26130736 doi: 10.1093/ndt/gfw165.07
Said, S. M. et al. Myeloproliferative neoplasms cause glomerulopathy. Kidney Int. 80, 753–759 (2011).
pubmed: 21654720 doi: 10.1038/ki.2011.147
Borza, D. B. et al. Recurrent Goodpasture’s disease secondary to a monoclonal IgA
pubmed: 15685519 doi: 10.1053/j.ajkd.2004.09.029
Coley, S. M., Shirazian, S., Radhakrishnan, J. & D’Agati, V. D. Monoclonal IgG
pubmed: 25446021 doi: 10.1053/j.ajkd.2014.08.022
Nasr, S. H. et al. The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis. Kidney Int. 89, 897–908 (2016).
pubmed: 26994577 doi: 10.1016/j.kint.2016.02.001
Debiec, H. et al. Recurrent membranous nephropathy in an allograft caused by IgG
pubmed: 23123401 pmcid: 3507371 doi: 10.1681/ASN.2012060577
Best Rocha, A. & Larsen, C. P. Membranous glomerulopathy with light chain-restricted deposits: a clinicopathological analysis of 28 cases. Kidney Int. Rep. 2, 1141–1148 (2017).
pubmed: 29270522 pmcid: 5733688 doi: 10.1016/j.ekir.2017.07.008
Dosa, S., Cairns, S. A., Mallick, N. P., Lawler, W. & Williams, G. Relapsing Henoch–Schönlein syndrome with renal involvement in a patient with an IgA monoclonal gammopathy. A study of the results of immunosuppressant and cytotoxic therapy. Nephron 26, 145–148 (1980).
pubmed: 6774272 doi: 10.1159/000181970
Zickerman, A. M. et al. IgA myeloma presenting as Henoch–Schönlein purpura with nephritis. Am. J. Kidney Dis. 36, E19 (2000).
pubmed: 10977812 doi: 10.1053/ajkd.2000.16221
Kyle, R. A. & Gertz, M. A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin. Hematol. 32, 45–59 (1995).
pubmed: 7878478
Randall, R. E., Williamson, W. C. Jr, Mullinax, F., Tung, M. Y. & Still, W. J. Manifestations of systemic light chain deposition. Am. J. Med. 60, 293–299 (1976).
pubmed: 814812 doi: 10.1016/0002-9343(76)90440-X
Landgren, O. et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107, 904–906 (2006).
pubmed: 16210333 pmcid: 1895893 doi: 10.1182/blood-2005-08-3449
Delanaye, P., Glassock, R. J., Pottel, H. & Rule, A. D. An age-calibrated definition of chronic kidney disease: rationale and benefits. Clin. Biochem. Rev. 37, 17–26 (2016).
pubmed: 27057075 pmcid: 4810758
Swaminathan, S. et al. Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. Clin. J. Am. Soc. Nephrol. 1, 483–487 (2006).
Soares, S. M. et al. Bleeding complications after transcutaneous kidney biopsy in patients with systemic amyloidosis: single-center experience in 101 patients. Am. J. Kidney Dis. 52, 1079–1083 (2008).
pubmed: 28057737 pmcid: 5394947 doi: 10.3324/haematol.2016.160408
Fish, R. et al. The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies. Clin. J. Am. Soc. Nephrol. 5, 1977–1980 (2010).
pubmed: 29351984 pmcid: 5830371 doi: 10.3324/haematol.2017.183749
Levi, I. M., Ben-Dov, I. Z., Klimov, A., Pizov, G. & Bloom, A. I. Transjugular kidney biopsy: enabling safe tissue diagnosis in high risk patients. Isr. Med. Assoc. J. 13, 425–427 (2011).
pubmed: 21838185
Thompson, B. C. et al. Transjugular kidney biopsy. Am. J. Kidney Dis. 43, 651–662 (2004).
pubmed: 15042542 doi: 10.1053/j.ajkd.2004.01.001
Huang, C. C. et al. IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression. Mod. Pathol. 26, 799–805 (2013).
pubmed: 23328976 doi: 10.1038/modpathol.2012.237
Bridoux, F. et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin. J. Am. Soc. Nephrol. 6, 2165–2174 (2011).
pubmed: 21784830 pmcid: 3358988 doi: 10.2215/CJN.06180710
Herrera, G. A. & Turbat-Herrera, E. A. Ultrastructural immunolabeling in the diagnosis of monoclonal light-and heavy-chain-related renal diseases. Ultrastruct. Pathol. 34, 161–173 (2010).
pubmed: 20455664 doi: 10.3109/01913121003672873
Herrera, G. A. The contributions of electron microscopy to the understanding and diagnosis of plasma cell dyscrasia-related renal lesions. Med. Electron. Microsc. 34, 1–18 (2001).
pubmed: 11479769 doi: 10.1007/s007950100000
Herrera, G. A. Renal manifestations of plasma cell dyscrasias: an appraisal from the patients’ bedside to the research laboratory. Ann. Diagn. Pathol. 4, 174–200 (2000).
pubmed: 10919389 doi: 10.1016/S1092-9134(00)90042-X
Vrana, J. A. et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 114, 4957–4959 (2009).
pubmed: 19797517 doi: 10.1182/blood-2009-07-230722
Mohamed, N. & Nasr, S. H. Renal amyloidosis. Surg. Pathol. Clin. 7, 409–425 (2014).
pubmed: 26837447 doi: 10.1016/j.path.2014.04.006
Royal, V. et al. IgD heavy-chain deposition disease: detection by laser microdissection and mass spectrometry. J. Am. Soc. Nephrol. 26, 784–790 (2015).
pubmed: 25194005 doi: 10.1681/ASN.2014050481
Leung, N., Barnidge, D. R. & Hutchison, C. A. Laboratory testing in monoclonal gammopathy of renal significance (MGRS). Clin. Chem. Lab. Med. 54, 929–937 (2016).
pubmed: 27107835 doi: 10.1515/cclm-2015-0994
Leung, N. et al. Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. Clin. J. Am. Soc. Nephrol. 7, 1964–1968 (2012).
pubmed: 23024162 pmcid: 3513751 doi: 10.2215/CJN.11161111
Katzmann, J. A. et al. Screening panels for detection of monoclonal gammopathies. Clin. Chem. 55, 1517–1522 (2009).
pubmed: 19520758 pmcid: 3773468 doi: 10.1373/clinchem.2009.126664
Palladini, G. et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 124, 2325–2332 (2014).
pubmed: 25115890 doi: 10.1182/blood-2014-04-570010
Palladini, G. et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J. Clin. Oncol. 30, 4541–4549 (2012).
pubmed: 23091105 doi: 10.1200/JCO.2011.37.7614
Hutchison, C. A. et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol. 9, 11 (2008).
pubmed: 18808676 pmcid: 2564915 doi: 10.1186/1471-2369-9-11
Kennard, A. et al. Comparison of Freelite and N Latex serum free light chain assays in subjects with end stage kidney disease on haemodialysis. Clin. Chem. Lab. Med. 54, 1045–1052 (2016).
pubmed: 26684350 doi: 10.1515/cclm-2015-0799
Dispenzieri, A. et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23, 215–224 (2009).
pubmed: 19020545 doi: 10.1038/leu.2008.307
Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328–e346 (2016).
pubmed: 27511158 doi: 10.1016/S1470-2045(16)30206-6
Treon, S. P. et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N. Engl. J. Med. 367, 826–833 (2012).
pubmed: 22931316 doi: 10.1056/NEJMoa1200710
Shanafelt, T. D., Ghia, P., Lanasa, M. C., Landgren, O. & Rawstron, A. C. Monoclonal B cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia 24, 512–520 (2010).
pubmed: 20090778 pmcid: 3913172 doi: 10.1038/leu.2009.287
Bochtler, T. et al. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. Amyloid 21, 9–17 (2014).
doi: 10.3109/13506129.2013.854766 pubmed: 24455967
Bochtler, T. et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J. Clin. Oncol. 33, 1371–1378 (2015).
pubmed: 25779559 doi: 10.1200/JCO.2014.57.4947
Muchtar, E. et al. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia 31, 1562–1569 (2017).
pubmed: 27904139 doi: 10.1038/leu.2016.369
Hillengass, J. et al. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Blood Cancer J. 7, e599 (2017).
pubmed: 28841211 pmcid: 5596388 doi: 10.1038/bcj.2017.78
Chantry, A. et al. Guidelines for the use of imaging in the management of patients with myeloma. Br. J. Haematol. 178, 380–393 (2017).
pubmed: 28677897 doi: 10.1111/bjh.14827
Landgren, O. MRD testing in multiple myeloma: from a surrogate marker of clinical outcomes to an every-day clinical tool. Semin. Hematol. 55, 1–3 (2018).
pubmed: 29759146 doi: 10.1053/j.seminhematol.2018.03.003
Palladini, G. et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin. Chem. 55, 499–504 (2009).
pubmed: 19131635 doi: 10.1373/clinchem.2008.117143
Wechalekar, A. D. et al. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood 112, 4009–4016 (2008).
pubmed: 18708629 doi: 10.1182/blood-2008-02-138156
Kourelis, T. V. et al. Outcomes of patients with renal monoclonal immunoglobulin deposition disease. Am. J. Hematol. 91, 1123–1128 (2016).
pubmed: 27501122 doi: 10.1002/ajh.24528
Ziogas, D. C. et al. Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. Leuk. Lymphoma 58, 1832–1839 (2017).
pubmed: 27967286 doi: 10.1080/10428194.2016.1267349
Messiaen, T. et al. Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. Medicine (Baltimore) 79, 135–154 (2000).
doi: 10.1097/00005792-200005000-00002
Brouet, J. C., Clauvel, J. P., Danon, F., Klein, M. & Seligmann, M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am. J. Med. 57, 775–788 (1974).
pubmed: 4216269 doi: 10.1016/0002-9343(74)90852-3
Bryce, A. H., Kyle, R. A., Dispenzieri, A. & Gertz, M. A. Natural history and therapy of 66 patients with mixed cryoglobulinemia. Am. J. Hematol. 81, 511–518 (2006).
pubmed: 16755564 doi: 10.1002/ajh.20643
Neel, A. et al. Long-term outcome of monoclonal (type 1) cryoglobulinemia. Am. J. Hematol. 89, 156–161 (2014).
pubmed: 24532335 doi: 10.1002/ajh.23608
Sidana, S. et al. Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. Am. J. Hematol. 92, 668–673 (2017).
pubmed: 28370486 pmcid: 5579826 doi: 10.1002/ajh.24745
Jones, D., Bhatia, V. K., Krausz, T. & Pinkus, G. S. Crystal-storing histiocytosis: a disorder occurring in plasmacytic tumors expressing immunoglobulin κ light chain. Hum. Pathol. 30, 1441–1448 (1999).
pubmed: 10667422 doi: 10.1016/S0046-8177(99)90166-1
Dotten, D. A., Pruzanski, W., Olin, J. & Brown, T. C. Cryocrystalglobulinemia. Can. Med. Assoc. J. 114, 909–912 (1976).
pubmed: 1268777 pmcid: 1957089
Javaugue, V. et al. Long-term kidney disease outcomes in fibrillary glomerulonephritis: a case series of 27 patients. Am. J. Kidney Dis. 62, 679–690 (2013).
pubmed: 23759297 doi: 10.1053/j.ajkd.2013.03.031

Auteurs

Nelson Leung (N)

Division of Nephrology, Hematology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. leung.nelson@mayo.edu.
ORCID: 0000-0002-5651-1411

Frank Bridoux (F)

Department of Nephrology, Centre Hospitalier Universitaire et Université de Poitiers, Poitiers, France; CNRS UMR7276, Limoges, France; and Centre de Référence Amylose AL et Autres Maladies par Dépôt d'Immunoglobulines Monoclonales, Poitiers, France.

Vecihi Batuman (V)

Veterans Administration Medical Center, New Orleans, LA, USA and Tulane University Medical School, Tulane, LA, USA.

Aristeidis Chaidos (A)

Centre for Haematology, Department of Medicine, Imperial College London and Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.

Paul Cockwell (P)

Department of Nephrology, Renal Medicine - University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, UK.

Vivette D D'Agati (VD)

Department of Pathology, Renal Pathology Laboratory, Columbia University, College of Physicians and Surgeons, New York, NY, USA.

Angela Dispenzieri (A)

Division of Nephrology, Hematology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Fernando C Fervenza (FC)

Division of Nephrology, Hematology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Jean-Paul Fermand (JP)

Department of Haematology and Immunology, University Hospital St Louis, Paris, France.

Simon Gibbs (S)

The Victorian and Tasmanian Amyloidosis Service, Department of Haematology, Monash Univerity Easter Health Clinical School, Melbourne, Victoria, Australia.

Julian D Gillmore (JD)

National Amyloidosis Centre, Centre for Amyloidosis and Acute Phase Proteins, Division of Medicine, Royal Free Campus, University College London, London, UK.

Guillermo A Herrera (GA)

Department of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center, Shreveport, LA, USA.

Arnaud Jaccard (A)

Service d'Hématologie et de Thérapie Cellulaire, Centre de Référence des Amyloses Primitives et des Autres Maladies par Dépôts d'Immunoglobuline, CHU Limoges, Limoges, France.

Dragan Jevremovic (D)

Division of Nephrology, Hematology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Efstathios Kastritis (E)

Department of Clinical Therapeutics, School of Medicine National and Kapodistrian University of Athens Alexandra Hospital, Athens, Greece.

Vishal Kukreti (V)

University Health Network, Princess Margaret Cancer Centre, Toronto, Canada.

Robert A Kyle (RA)

Division of Nephrology, Hematology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Helen J Lachmann (HJ)

National Amyloidosis Centre, Centre for Amyloidosis and Acute Phase Proteins, Division of Medicine, Royal Free Campus, University College London, London, UK.

Christopher P Larsen (CP)

Arkana Laboratories, Little Rock, AR, USA.

Heinz Ludwig (H)

Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria.

Glen S Markowitz (GS)

Department of Pathology, Renal Pathology Laboratory, Columbia University, College of Physicians and Surgeons, New York, NY, USA.

Giampaolo Merlini (G)

Amyloidosis Research and Treatment Center, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.

Peter Mollee (P)

Haematology Department, Princess Alexandra Hospital and School of Medicine, University of Queensland, Brisbane, Australia.

Maria M Picken (MM)

Department of Pathology, Loyola University Medical Center, Maywood, IL, USA.

Vincent S Rajkumar (VS)

Division of Nephrology, Hematology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Virginie Royal (V)

Department of Pathology, Hôpital Maisonneuve-Rosemont, Université de Montreal, Montreal, Quebec, Canada.

Paul W Sanders (PW)

Department of Medicine, University of Alabama at Birmingham and Department of Veterans Affairs Medical Center, Birmingham, AL, USA.
ORCID: 0000-0002-2915-5714

Sanjeev Sethi (S)

Division of Nephrology, Hematology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
ORCID: 0000-0002-4536-7709

Christopher P Venner (CP)

Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.

Peter M Voorhees (PM)

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium System, Charlotte, NC, USA.

Ashutosh D Wechalekar (AD)

National Amyloidosis Centre, Centre for Amyloidosis and Acute Phase Proteins, Division of Medicine, Royal Free Campus, University College London, London, UK.

Brendan M Weiss (BM)

Abramson Cancer Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.

Samih H Nasr (SH)

Division of Nephrology, Hematology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › The evaluation of monoclonal gammopathy of...
questionsmedicales.fr › Techniques d'investigation › Techniques cytologiques › Cytodiagnostic › Biopsie › The evaluation of monoclonal gammopathy of...
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Services de santé › Services de médecine préventive › Services de diagnostic › Dépistage génétique › The evaluation of monoclonal gammopathy of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The evaluation of monoclonal gammopathy of...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Maladies du rein › The evaluation of monoclonal gammopathy of...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Paraprotéinémies › The evaluation of monoclonal gammopathy of...